WARPTECHNEWS · LAB

Home AI Business Tech Archive

GSK ends brain drug alliance with Alector — Warptech Lab News

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

biopharmadive.com

GSK ends brain drug alliance with Alector

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

giovedì 9 luglio 2026 New tab

453 words~2 min read

An article from

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK’s return to neuroscience.

Published July 9, 2026

A GSK logo is seen on the side of an office building in Poznan, Poland.

Getty Images

Other newsrooms on this story

· 5 sources

Full timeline →

endpoints.news·Jul 9, 2026 · 1 mese fa
GSK walks away from Alector pact as immuno-neurology bet fizzles
benzinga.com·Jul 10, 2026 · 1 mese fa
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - GSK (NYSE:GSK)
fiercepharma.com·Jul 7, 2026 · 1 mese fa
Bristol lays out KRAS med Krazati's stumble in confirmatory colorectal cancer trial
fiercepharma.com·Jul 13, 2026 · 1 mese fa
GSK to seek FDA approval for Jemperli in small but high-profile cancer use after phase 2 win
benzinga.com·Jul 13, 2026 · 1 mese fa
What's Going on With GSK Stock Monday? - GSK (NYSE:GSK)

Related reading

GSK walks away from Alector pact as immuno-neurology bet fizzles

GSK terminates its Alector pact after back-to-back Phase 2/3 flops in dementia and Alzheimer's, leaving Alector's pipeline…

endpoints.news·1 mese fa

GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - GSK…

GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company moves to end its collaboration…

benzinga.com·1 mese fa

biopharmadive.com

GSK shelves cough drug acquired in $2B deal

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to…

biopharmadive.com·1 mese fa

biopharmadive.com

GSK lung cancer drug gets speedy approval following $10.6B deal

The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker…

biopharmadive.com·1 mese fa

biopharmadive.com

Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda

Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an…

biopharmadive.com·2 mesi fa

Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3

Incyte drops JAK2 drug INCB160058 after data review; Oak Hill Bio merges with RA Capital SPAC for $175M; Innocare's…

endpoints.news·28 g fa